Researchers Identify Molecule that Reduces Fats in Blood Circulation
Jun 12, 2013
Discovery May Prove Useful in Fighting Cardiovascular Disease
Brooklyn – Hyperlipidemia, a condition with high levels of fats circulating in the
bloodstream, is a known risk factor for various cardiovascular and metabolic disorders.
While the Western diet often contributes to high levels of lipids such as cholesterol
and triglycerides, over-production of the body’s own lipoproteins can lead to hyperlipidemia,
independent of food intake.
In a discovery that may pave the way towards new treatments for high cholesterol,
researchers led by M. Mahmood Hussain, PhD, Professor of Cell Biology at SUNY Downstate
Health Sciences University, found that a regulatory RNA molecule interferes with the
production of lipoproteins and, in a mouse model, reduces hyperlipidemia and atherosclerosis.
Their study was published recently in the online edition of Nature Medicine .
Dr. Hussain, whose laboratory focuses on molecular mechanisms of intestinal lipoprotein
assembly, says, “High plasma lipid and lipoprotein levels are a risk factor for atherosclerosis,
and lowering plasma lipid levels is a national goal. While current medications and
changes in diet can be effective, cardiovascular disease remains the number one cause
of death in the United States, and additional approaches to decrease lipid levels
are needed.”
In their Nature Medicine article, Dr. Hussain and colleagues note that “overproduction of lipoproteins, a
process that is dependent on microsomal triglyceride transfer protein (MTP), can contribute
to hyperlipidemia.” They demonstrate that microRNA-30c (miR-30c), a genetic regulator,
interacts with MTP and induces its degradation, leading to reductions in MTP activity,
the production of lipoproteins, plasma lipids, and atherosclerosis. This molecule
also reduces lipid synthesis independently of MTP thereby avoiding complications associated
with drug therapies aimed at lowering lipoprotein production.
The authors conclude that a medication mimicking miR-30c could potentially be effective
in reducing hyperlipidemia in humans.
This work was supported in part by U.S. National Institutes of Health grants R01DK046900,
from the National Institute of Diabetes and Digestive and Kidney Diseases, and R01HL095924,
from the National Heart, Lung and Blood Institute.
A link to the article, “MicroRNA-30c reduces hyperlipidemia and atherosclerosis in
mice by decreasing lipid synthesis and lipoprotein secretion,” follows below. The
content is solely the responsibility of the authors and does not necessarily represent
the official views of the National Institutes of Health.
http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.3200.html
###
About SUNY Downstate Health Sciences University
Downstate Health Sciences University in Brooklyn is one of four academic health centers (AMCs) in The State University of New York (SUNY) 64-campus system and the only SUNY AMC in New York City dedicated to health education, research, and patient care for the borough’s 2.7 million residents. Its flagship hospital, University Hospital at Downstate (UHD), is a teaching hospital and benefits from the expertise of Downstate’s exceptional medical school and world-class academic center research facilities. With a staff of over 800 physicians representing 53 specialties and subspecialties, Downstate offers comprehensive healthcare services to the community.
UHD provides high-risk neonatal and infant services, pediatric nephrology, and dialysis for kidney diseases and is the only kidney transplantation program in Brooklyn. Beyond its clinical expertise, Downstate houses a range of esteemed educational institutions, including its College of Medicine, College of Nursing, School of Health Professions, School of Graduate Studies, and School of Public Health. Downstate fosters innovation through its multifaceted biotechnology initiative, the Biotechnology Incubator and BioBAT, which support early-stage and more mature biotech companies.